Management
In a randomized trial [PMID:30803411], 51 out of 53 patients remained euthyroid with continuous MMI treatment over 60-100 months, with a median dosage of 4.1 mg daily in the fifth year.
Among patients treated with RAI [PMID:30803411], 41% became hypothyroid, while only 3.8% of those on MMI experienced subclinical hypothyroidism.
Complications
During the initial months of MMI treatment [PMID:30803411], some patients experienced elevated liver enzymes and skin reactions, but no adverse effects were noted after the first three months over a follow-up period of 4 to 100 months.
References
1 Azizi F, Takyar M, Madreseh E, Amouzegar A. Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment. Thyroid : official journal of the American Thyroid Association 2019. link
1 papers cited of 3 indexed.